Effects of DHMEQ, a novel nuclear factor-κB inhibitor, on beta cell dysfunction in INS-1 cells

Yoshifumi Saisho, Hiroshi Hirose, Chihiro Horimai, Kiichi Miyashita, Izumi Takei, Kazuo Umezawa, Hiroshi Itoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: Recent studies suggest that nuclear factor-κB (NF-κB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study we tested this hypothesis by investigating the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, on tumor necrosis factor-α (TNF-α)-induced beta cell dysfunction. Methods: INS-1 cells were incubated with TNF-α and with or without DHMEQ for 24 hours. Glucose-stimulated insulin secretion, cell viability, mRNA expression and NF-?̂B activation were investigated. Results: DHMEQ suppressed TNF-α-induced NF-κB activation and partially ameliorated glucose-stimulated insulin secretion in a dose-dependent manner. DHMEQ also partially ameliorated decreased cell viability and insulin mRNA level induced by TNF-α. Conclusion: DHMEQ suppressed NF-κB activation and ameliorated beta cell dysfunction induced by TNF-α. Inhibition of activated NF-κB in beta cells may be important to ameliorate beta cell dysfunction in diabetes.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalEndocrine Journal
Volume55
Issue number2
DOIs
Publication statusPublished - 2008

Fingerprint

Tumor Necrosis Factor-alpha
Insulin
Cell Survival
Glucose
Lymphotoxin-alpha
Messenger RNA
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
dehydroxymethylepoxyquinomicin

Keywords

  • Cell viability
  • Dehydroxymethylepoxyquinomicin
  • Glucose-stimulated insulin secretion
  • INS-1 cells
  • Nuclear factor-κB
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of DHMEQ, a novel nuclear factor-κB inhibitor, on beta cell dysfunction in INS-1 cells. / Saisho, Yoshifumi; Hirose, Hiroshi; Horimai, Chihiro; Miyashita, Kiichi; Takei, Izumi; Umezawa, Kazuo; Itoh, Hiroshi.

In: Endocrine Journal, Vol. 55, No. 2, 2008, p. 433-438.

Research output: Contribution to journalArticle

Saisho, Yoshifumi ; Hirose, Hiroshi ; Horimai, Chihiro ; Miyashita, Kiichi ; Takei, Izumi ; Umezawa, Kazuo ; Itoh, Hiroshi. / Effects of DHMEQ, a novel nuclear factor-κB inhibitor, on beta cell dysfunction in INS-1 cells. In: Endocrine Journal. 2008 ; Vol. 55, No. 2. pp. 433-438.
@article{c4e56f2d330c45829291d3bf8e585dbb,
title = "Effects of DHMEQ, a novel nuclear factor-κB inhibitor, on beta cell dysfunction in INS-1 cells",
abstract = "Aims: Recent studies suggest that nuclear factor-κB (NF-κB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study we tested this hypothesis by investigating the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, on tumor necrosis factor-α (TNF-α)-induced beta cell dysfunction. Methods: INS-1 cells were incubated with TNF-α and with or without DHMEQ for 24 hours. Glucose-stimulated insulin secretion, cell viability, mRNA expression and NF-?̂B activation were investigated. Results: DHMEQ suppressed TNF-α-induced NF-κB activation and partially ameliorated glucose-stimulated insulin secretion in a dose-dependent manner. DHMEQ also partially ameliorated decreased cell viability and insulin mRNA level induced by TNF-α. Conclusion: DHMEQ suppressed NF-κB activation and ameliorated beta cell dysfunction induced by TNF-α. Inhibition of activated NF-κB in beta cells may be important to ameliorate beta cell dysfunction in diabetes.",
keywords = "Cell viability, Dehydroxymethylepoxyquinomicin, Glucose-stimulated insulin secretion, INS-1 cells, Nuclear factor-κB, Tumor necrosis factor-α",
author = "Yoshifumi Saisho and Hiroshi Hirose and Chihiro Horimai and Kiichi Miyashita and Izumi Takei and Kazuo Umezawa and Hiroshi Itoh",
year = "2008",
doi = "10.1507/endocrj.K07E-036",
language = "English",
volume = "55",
pages = "433--438",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Effects of DHMEQ, a novel nuclear factor-κB inhibitor, on beta cell dysfunction in INS-1 cells

AU - Saisho, Yoshifumi

AU - Hirose, Hiroshi

AU - Horimai, Chihiro

AU - Miyashita, Kiichi

AU - Takei, Izumi

AU - Umezawa, Kazuo

AU - Itoh, Hiroshi

PY - 2008

Y1 - 2008

N2 - Aims: Recent studies suggest that nuclear factor-κB (NF-κB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study we tested this hypothesis by investigating the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, on tumor necrosis factor-α (TNF-α)-induced beta cell dysfunction. Methods: INS-1 cells were incubated with TNF-α and with or without DHMEQ for 24 hours. Glucose-stimulated insulin secretion, cell viability, mRNA expression and NF-?̂B activation were investigated. Results: DHMEQ suppressed TNF-α-induced NF-κB activation and partially ameliorated glucose-stimulated insulin secretion in a dose-dependent manner. DHMEQ also partially ameliorated decreased cell viability and insulin mRNA level induced by TNF-α. Conclusion: DHMEQ suppressed NF-κB activation and ameliorated beta cell dysfunction induced by TNF-α. Inhibition of activated NF-κB in beta cells may be important to ameliorate beta cell dysfunction in diabetes.

AB - Aims: Recent studies suggest that nuclear factor-κB (NF-κB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study we tested this hypothesis by investigating the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, on tumor necrosis factor-α (TNF-α)-induced beta cell dysfunction. Methods: INS-1 cells were incubated with TNF-α and with or without DHMEQ for 24 hours. Glucose-stimulated insulin secretion, cell viability, mRNA expression and NF-?̂B activation were investigated. Results: DHMEQ suppressed TNF-α-induced NF-κB activation and partially ameliorated glucose-stimulated insulin secretion in a dose-dependent manner. DHMEQ also partially ameliorated decreased cell viability and insulin mRNA level induced by TNF-α. Conclusion: DHMEQ suppressed NF-κB activation and ameliorated beta cell dysfunction induced by TNF-α. Inhibition of activated NF-κB in beta cells may be important to ameliorate beta cell dysfunction in diabetes.

KW - Cell viability

KW - Dehydroxymethylepoxyquinomicin

KW - Glucose-stimulated insulin secretion

KW - INS-1 cells

KW - Nuclear factor-κB

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=43449092909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449092909&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K07E-036

DO - 10.1507/endocrj.K07E-036

M3 - Article

C2 - 18385532

AN - SCOPUS:43449092909

VL - 55

SP - 433

EP - 438

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 2

ER -